149 COMMONWEALTH DRIVE, MENLO PARK, CA
FDA Approves Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Provides Update on Patent Dispute with Teva Pharmaceuticals
Overall Survival Primary Endpoint Met in Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Termination of Distribution Services Agreement with Optime Care, Inc.
News
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
S-8 POS